Results 141 to 150 of about 48,035 (283)

Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy—A Comprehensive Review

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad, YuZhu Jin, Kai Luo, He Bai, Xudong Zhang, Xu Sun, Zahoor Maheen, Ali Tanveer, Saeed Muddasar Muhammad, Jialin Qu, Guixin Zhang   +10 more
wiley   +1 more source

Microscopic colitis and primary sclerosing cholangitis are bidirectionally associated: A nationwide matched cohort and case–control study

Journal of Internal Medicine, EarlyView.
Abstract Background Microscopic colitis (MC) is an inflammatory disease of the colon. Although there is a known association between inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC), evidence linking MC and PSC remains scarce. We aimed to investigate the bidirectional association between MC and PSC.
David Bergman, Anders Forss, Jiangwei Sun, Fahim Ebrahimi, Björn Lindkvist, Charlotte Hedin, Hannes Hagström, Annika Bergquist, Jialu Yao, Jonas F. Ludvigsson   +9 more
wiley   +1 more source

Efficiency and Safety of Endoscopic Injection Sclerotherapy With Ligation for Esophageal Varices: A Retrospective Study.

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Objectives Endoscopic injection sclerotherapy with ligation (EISL) is a combined endoscopic treatment that involves endoscopic injection sclerotherapy (EIS) and endoscopic variceal ligation. This study aimed to compare the efficacy of conventional EIS and EISL in treating esophageal varices and the usefulness of EISL.
Keita Maki, Hiroaki Haga, Kyoko Hoshikawa, Tomohiro Katsumi, Fumiya Suzuki, Fumi Uchiyama, Yoshiyuki Ueno   +6 more
wiley   +1 more source

Phase I/II Prospective Study on Endoscopic Ultrasound‐Guided Hepaticogastrostomy as Primary Drainage for Unresectable Malignant Hilar Biliary Obstruction

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Objectives Various drainage methods have been used for unresectable malignant hilar biliary obstruction (MHBO). However, controlling cholangitis and obstructive jaundice is still challenging. We performed a phase I/II study of endoscopic ultrasound‐guided hepaticogastrostomy (EUS‐HGS) as primary drainage for MHBO.
Tomoki Ogata, Kazuo Hara, Nozomi Okuno, Shin Haba, Takamichi Kuwahara, Shimpei Matsumoto, Hiroki Koda, Keigo Oshiro   +7 more
wiley   +1 more source

Novel Clinical and Histological Insights into Cutaneous Kikuchi‐Fujimoto Disease and Kikuchi Disease‐Like Inflammatory Pattern (KLIP)

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Magí Brufau‐Cochs, Xavier Bosch‐Amate, Javier Gil‐Lianes, Natalia Castrejón de Anta, Pilar Iranzo, Priscila Giavedoni, Adriana García‐Herrera, José M. Mascaró Jr.   +7 more
wiley   +1 more source

Optimal Stenting Strategy During Chemotherapy: Impact of Time to First Reintervention on Survival in Malignant Hilar Biliary Obstruction

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Objectives Advances in chemotherapy have increased survival in biliary tract cancer patients, and reports of the effectiveness of neoadjuvant therapy are emerging. Accordingly, developing optimal drainage strategies under chemotherapy is important.
Katsuhiko Sato, Minoru Shigekawa, Teppei Yoshioka, Kazuma Daiku, Syuhei Yamamoto, Yu Sato, Takahiro Kodama, Hayato Hikita, Tetsuo Takehara   +8 more
wiley   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Clinical and Demographic Features of Primary Biliary Cholangitis in Kazakhstan. [PDF]

Diseases
Gainutdin A, Nersesov A, Atsumasa K, Raissova A, Madenova S, Yerdaliyeva L, Suleimenova D, Issenova B.   +7 more
europepmc   +1 more source

Sclerosing cholangitis: Liver transplantation [PDF]

, 1989
Marsh, JW, Starzl, TE
core  

Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1584-1596, June 2026.
Pediatric populations differ from adults in drug elimination capacity. While current scaling methods account for enzyme and transporter maturation, they overlook comorbidities, such as biliary atresia (BA), a liver disease appearing within the first 2–8 weeks of life that can progress to cirrhosis.
Zubida M. Al‐Majdoub, Martyn Howard, Brahim Achour, Jill Barber, Naved Alizai, Amin Rostami‐Hodjegan   +5 more
wiley   +1 more source